Q-omics provides the consensus-scored GRIA2 profile across patient tissues and cancer cell-line models. GRIA2 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, GRIA2 is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, GRIA2 protein abundance shows 17,971 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight LIHC, COAD, and GBM as cancer lineages where GRIA2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GRIA2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GRIA2 survival associations across molecular data types. GRIA2 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (6) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GRIA2 RNA expression–survival associations across cancer types. High GRIA2 expression shows unfavorable associations in LIHC, BLCA, KIRP, UVM and KICH, but favorable associations in LGG. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for GRIA2 RNA expression.
This table summarizes GRIA2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for GRIA2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GRIA2 shows lower tumor expression in COAD, KIRP, KIRC, KICH and STAD and higher tumor expression in BRCA. The COAD box plot shows higher GRIA2 RNA expression in normal versus tumor tissue (log2 FC = −0.065, t-test p < 0.001).
This table shows molecular features associated with GRIA2 in patient tissues and cancer cell lines. In patient samples, GRIA2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, GRIA2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in OVARY and LARGE_INTESTINE.
